DK3677591T3 - Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b - Google Patents

Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b Download PDF

Info

Publication number
DK3677591T3
DK3677591T3 DK19213030.0T DK19213030T DK3677591T3 DK 3677591 T3 DK3677591 T3 DK 3677591T3 DK 19213030 T DK19213030 T DK 19213030T DK 3677591 T3 DK3677591 T3 DK 3677591T3
Authority
DK
Denmark
Prior art keywords
fusions
antibodies
interferon alpha
attenuated interferon
attenuated
Prior art date
Application number
DK19213030.0T
Other languages
English (en)
Inventor
Adam Clarke
Matthew Pollard
Anthony Gerard Doyle
Collette Behrens
Tetsuo Yamagishi
David S Wilson Jr
Sarah L Pogue
Tetsuya Taura
Original Assignee
Teva Pharmaceuticals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Australia Pty Ltd filed Critical Teva Pharmaceuticals Australia Pty Ltd
Application granted granted Critical
Publication of DK3677591T3 publication Critical patent/DK3677591T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
DK19213030.0T 2013-04-29 2013-04-29 Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b DK3677591T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13721243.7A EP2992013B1 (en) 2013-04-29 2013-04-29 Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
EP19213030.0A EP3677591B1 (en) 2013-04-29 2013-04-29 Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
PCT/US2013/038659 WO2014178820A1 (en) 2013-04-29 2013-04-29 Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b

Publications (1)

Publication Number Publication Date
DK3677591T3 true DK3677591T3 (da) 2023-03-20

Family

ID=48325957

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19213030.0T DK3677591T3 (da) 2013-04-29 2013-04-29 Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b

Country Status (23)

Country Link
US (1) US9963515B2 (da)
EP (2) EP3677591B1 (da)
JP (1) JP6286532B2 (da)
KR (1) KR102094022B1 (da)
CN (2) CN105473615B (da)
AU (2) AU2013388126B2 (da)
BR (1) BR112015027313A2 (da)
CA (1) CA2909952C (da)
DK (1) DK3677591T3 (da)
EA (1) EA033115B1 (da)
ES (2) ES2938708T3 (da)
FI (1) FI3677591T3 (da)
HK (1) HK1216650A1 (da)
IL (1) IL242296B (da)
MX (1) MX370377B (da)
NZ (1) NZ713641A (da)
PH (1) PH12015502439B1 (da)
PL (2) PL3677591T3 (da)
PT (2) PT2992013T (da)
SG (1) SG11201508923VA (da)
UA (1) UA113129C2 (da)
WO (1) WO2014178820A1 (da)
ZA (1) ZA201507789B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201700111A1 (ru) 2011-10-28 2018-02-28 Тева Фармасьютикал Австралия Пти Лтд Полипептидные конструкции и их применение
LT2822575T (lt) 2012-03-03 2020-06-25 Immungene, Inc. Sukonstruotos antikūno-mutantinio interferono sulietos molekulės
EP2900232B1 (en) 2012-09-25 2017-11-15 MorphoSys AG Combinations and uses thereof
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
AU2015315396B2 (en) 2014-09-09 2020-10-08 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016065409A1 (en) 2014-10-29 2016-05-06 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
UA124143C2 (uk) 2015-05-20 2021-07-28 Янссен Байотек, Інк. Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень
CA2990406A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
PE20181090A1 (es) 2015-06-24 2018-07-09 Janssen Biotech Inc Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US20180155411A1 (en) * 2015-07-08 2018-06-07 The Board Of Trustees Of The Leland Stanford Junior University Heterotypic antibodies specific for human rotavirus
SI3370770T1 (sl) 2015-11-03 2021-03-31 Janssen Biotech, Inc. Subkutane formulacije protiteles proti CD38 in njihove uporabe
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
IL305540A (en) 2016-03-04 2023-10-01 Morphosys Ag Clinical evaluation of protein-M response in multiple myeloma
EP3474895A1 (en) 2016-06-28 2019-05-01 UMC Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
WO2018014068A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Attenuated type i ifn cd47 combination therapy
EP3487522A4 (en) * 2016-07-19 2020-04-01 Teva Pharmaceuticals Australia Pty Ltd ANTI-CD47 COMBINATION THERAPY
JP2019521171A (ja) 2016-07-20 2019-07-25 ヒブリジェニクス・エスアー 抗ｃｄ３８薬剤とのイネカルシトールの組み合わせ、及び癌を治療するためのその使用
WO2018022628A1 (en) * 2016-07-25 2018-02-01 Cephalon, Inc. Affinity chromatography wash buffer
WO2018237159A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. WASH PAD FOR CATIONIC EXCHANGE CHROMATOGRAPHY
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
JP6648171B2 (ja) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
JP2022512722A (ja) 2018-10-17 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下投与を提供する方法
AU2019395841A1 (en) 2018-12-14 2021-05-20 Morphosys Ag Antibody formulations
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
IL295210B2 (en) 2020-02-16 2024-04-01 Aulos Bioscience Inc Transgenic antibodies against 2–IL
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
WO2023016564A1 (zh) * 2021-08-12 2023-02-16 上海才致药成生物科技有限公司 靶向GPC3的抗体干扰素α融合蛋白及其用途
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023223100A1 (en) * 2022-05-18 2023-11-23 Takeda Pharmaceutical Company Limited Anti-cd38 fusion protein formulation

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5558864A (en) 1991-03-06 1996-09-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
TW205553B (da) 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
HU221001B1 (hu) 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU719513B2 (en) 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
EP1121382B9 (en) 1998-10-16 2007-07-04 Biogen Idec MA Inc. Interferon-beta fusion proteins and uses
PT1137789E (pt) 1998-12-09 2010-10-21 Phyton Holdings Llc Um método para produzir glicoproteínas possuindo glicosilação de tipo humano
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US7355015B1 (en) 1999-03-12 2008-04-08 Georgetown University School Of Medicine Matriptase, a serine protease and its applications
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
CA2412901A1 (en) * 2000-06-22 2001-12-27 Idec Pharmaceutical Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
ATE464322T1 (de) 2001-01-05 2010-04-15 Pfizer Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
ATE433996T1 (de) 2001-07-03 2009-07-15 Genentech Inc Humane dr4-antikörper und deren anwendungen
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2003059282A2 (en) 2002-01-09 2003-07-24 Medarex, Inc. Human monoclonal antibodies against cd30
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1594965A2 (en) 2003-02-18 2005-11-16 MERCK PATENT GmbH Fusion proteins of interferon alpha muteins with improved properties
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
DE10343708A1 (de) 2003-09-18 2005-05-12 Nexpress Solutions Llc Verfahren für das Befestigen von Toner an einem Bedruckstoff und Mikrowelleneinrichtung
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
SG142330A1 (en) * 2004-02-06 2008-05-28 Morphosys Ag De Anti-cd38 human antibodies and uses therefor
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
US8034352B2 (en) 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
WO2005086875A2 (en) 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP5112863B2 (ja) 2004-07-01 2013-01-09 ノヴォ ノルディスク アー／エス ヒト抗−ｋｉｒ抗体
WO2006044643A2 (en) 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
CA2609613A1 (en) 2005-05-26 2006-11-30 Schering Corporation Interferon-igg fusion
EP1909822B1 (en) 2005-06-29 2013-09-25 Yeda Research And Development Co., Ltd. Recombinant interferon alpha 2 (ifn alpha 2) mutants
NZ625807A (en) 2005-07-18 2015-11-27 Amgen Inc Human anti-b7rp1 neutralizing antibodies
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
CN106434683B (zh) 2005-10-12 2020-03-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
AU2006308648A1 (en) 2005-10-31 2007-05-10 Duke University Antibodies and immunotoxins that target human glycoprotein NMB
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CN101045156B (zh) 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
AU2007299843B2 (en) * 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
CA2664740C (en) 2006-09-26 2021-11-16 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
WO2008145139A1 (en) 2007-05-31 2008-12-04 Genmab A/S Fusion or linked proteins with extended half life
AU2008282729B2 (en) 2007-08-01 2015-07-16 Scott & White Healthcare A fold-back diabody diphtheria toxin immunotoxin and methods of use
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
BRPI0817108B8 (pt) 2007-09-21 2021-05-25 Univ California composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009080829A1 (en) 2007-12-26 2009-07-02 Biotest Ag Agents targeting cd138 and uses thereof
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
MA33194B1 (fr) 2009-03-16 2012-04-02 Cephalon Australia Pty Ltd Anticorps humanisés ayant une activité antitumorale
RS59769B1 (sr) * 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
MX350540B (es) 2010-09-27 2017-09-08 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl.
CN103429261A (zh) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EA201700111A1 (ru) 2011-10-28 2018-02-28 Тева Фармасьютикал Австралия Пти Лтд Полипептидные конструкции и их применение
AU2013211059B8 (en) 2012-01-20 2017-12-21 Centre Hospitalier Regional Universitaire De Montpellier Targeted mutant alpha-helical bundle cytokines
LT2822575T (lt) 2012-03-03 2020-06-25 Immungene, Inc. Sukonstruotos antikūno-mutantinio interferono sulietos molekulės
US9783589B2 (en) 2012-08-13 2017-10-10 Immungene Inc Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016065409A1 (en) 2014-10-29 2016-05-06 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS

Also Published As

Publication number Publication date
EP3677591B1 (en) 2022-12-28
MX2015015043A (es) 2016-08-11
ES2938708T3 (es) 2023-04-14
EA201592076A1 (ru) 2016-07-29
EP2992013A1 (en) 2016-03-09
EP3677591A1 (en) 2020-07-08
CA2909952C (en) 2021-10-12
CN110526971B (zh) 2023-06-30
JP6286532B2 (ja) 2018-02-28
AU2019204016B2 (en) 2021-03-25
SG11201508923VA (en) 2015-11-27
BR112015027313A2 (pt) 2017-09-26
AU2013388126B2 (en) 2019-03-07
WO2014178820A1 (en) 2014-11-06
EA033115B1 (ru) 2019-08-30
PL3677591T3 (pl) 2023-06-26
CN110526971A (zh) 2019-12-03
NZ713641A (en) 2019-08-30
ZA201507789B (en) 2017-01-25
AU2019204016A1 (en) 2019-06-27
CN105473615A (zh) 2016-04-06
CN105473615B (zh) 2019-05-07
EP2992013B1 (en) 2019-12-04
PT3677591T (pt) 2023-02-17
KR20160002864A (ko) 2016-01-08
PT2992013T (pt) 2020-03-05
CA2909952A1 (en) 2014-11-06
HK1216650A1 (zh) 2016-11-25
PH12015502439A1 (en) 2016-03-28
ES2774976T3 (es) 2020-07-23
IL242296B (en) 2020-06-30
US20160068612A1 (en) 2016-03-10
UA113129C2 (xx) 2016-12-12
MX370377B (es) 2019-12-11
AU2013388126A1 (en) 2015-11-12
FI3677591T3 (fi) 2023-04-03
US9963515B2 (en) 2018-05-08
PH12015502439B1 (en) 2016-03-28
PL2992013T3 (pl) 2020-09-07
KR102094022B1 (ko) 2020-03-30
JP2016522816A (ja) 2016-08-04

Similar Documents

Publication Publication Date Title
DK3677591T3 (da) Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
HRP20181478T1 (hr) Humanizirani anti-cd134 (ox40) protutijela i njihove uporabe
IL269226A (en) Antibodies that bind to TL1A and uses thereof
CL2016001646A1 (es) Anticuerpos y fragmentos anti-vista
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3019533T3 (da) Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf
HK1221725A1 (zh) 纖溶酶原激活劑抑制劑- 的抗體及其用途
DK3406633T3 (da) Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
DK3192812T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK3019200T3 (da) Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
DK2953976T3 (da) Specifikke modificeringssteder i antistoffer til fremstilling af immunkonjugater
DK3686280T3 (da) Carbohydratdegraderende polypeptid og anvendelser deraf
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
IL244018A0 (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
CL2015002750A1 (es) Anticuerpos humanos pac1
DK3027564T3 (da) Nedsænket forbrændingssmelter og fremgangsmåde
DK3456344T3 (da) Proteiner, der er specifikke for baff og b7rp1, og anvendelser deraf
EP3008930A4 (en) FRAMEWORK AND APPLICATIONS FOR NEARBY-BASED SOCIAL INTERACTION
HK1220474A1 (zh) 干擾素α和ω抗體拮抗劑
DK3019525T3 (da) Antistoffer til beta2-glycoprotein i og terapeutiske anvendelser deraf